Chemoprevention strategies 2006

Area of Science:

• Oncology
• Pharmacology
• Preventive Medicine

Background:

• Prospective trials have assessed tamoxifen for breast cancer risk reduction in high-risk women.
• Breast cancer risk is a key factor determining the net benefit of tamoxifen therapy.
• Age and factors increasing toxicity risk significantly impact tamoxifen's net benefit.

Purpose of the Study:

• To evaluate the comparative efficacy and safety of tamoxifen and raloxifene for breast cancer risk reduction.
• To identify patient populations that derive the greatest net benefit from these chemopreventive agents.
• To analyze the trade-offs between benefits (risk reduction, fracture prevention) and risks (side effects, thromboembolic events).

Main Methods:

• Review of prospective clinical trials comparing tamoxifen and placebo.
• Analysis of raloxifene's effects on invasive and in situ breast cancer risk in postmenopausal women.
• Comparative assessment of tamoxifen and raloxifene in specific risk groups, including premenopausal and postmenopausal women.

Main Results:

• Tamoxifen provides greater clinical benefit with fewer side effects in younger, premenopausal women, those without a uterus, and women with higher breast cancer risk (e.g., atypical hyperplasia, lobular carcinoma in situ).
• Raloxifene reduces invasive breast cancer risk in postmenopausal women, comparable to tamoxifen in younger postmenopausal women at increased risk.
• Raloxifene may be less effective than tamoxifen for reducing in situ breast cancer risk, but offers net benefits in high-risk, younger, postmenopausal women when considering fracture prevention alongside cancer risk reduction.

Conclusions:

• Tamoxifen's benefit is maximized in younger, premenopausal women and those with specific risk factors, minimizing toxicity.
• Raloxifene is an alternative for postmenopausal women, particularly for invasive breast cancer risk reduction and fracture prevention, though potentially less effective for in situ disease.
• Personalized risk assessment is crucial for selecting the optimal agent (tamoxifen or raloxifene) to maximize net benefit and minimize adverse events in breast cancer prevention.